Abstracts from Hydrocephalus World Congress 2025

taining blinding.Patients and assessors were blinded to treatment assignment.Assessors were trained in gait and cognitive assessments.Quality control reviews were conducted.Secondary outcome measures included cognitive assessments (MoCA, SDMT), functional scales for bladder control, activities of daily living (ADLs), depression, quality of life, and complications.Results: Target enrollment (n=99) was completed in January 2025.The planned interim analysis included 74 participants (38 Active, 36 Placebo), mean age 75.0±5.4,50% female.We will present results of the primary outcome (gait velocity) and secondary outcome measures 3 months after surgery, comparing Placebo vs Active shunting.Conclusion: This multicenter, randomized, blinded, placebo-controlled trial, which aimed to evaluate the effectiveness and safety of shunting in iNPH, has completed enrollment, and interim data will be presented.Assessments for 12-month outcomes are ongoing.